Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent
February 17 2023 - 8:08AM
Business Wire
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court
of Appeals for the Federal Circuit unanimously affirmed a 2021
district court ruling that invalidated a Minerva patent asserted
against Hologic. The appellate court ruled that Minerva’s patent is
invalid because it waited more than a year to file a patent
application after showing a prototype of the invention at a trade
show.
“We are pleased with the U.S. Court of Appeals decision to
invalidate Minerva’s patent. It confirms our belief from the
beginning that Minerva’s lawsuit lacked merit,” said Essex
Mitchell, President, Hologic GYN Surgical Solutions Division.
In 2017, Minerva alleged that Hologic’s NovaSure® Advanced
endometrial ablation system infringed a Minerva patent. In 2021,
the district court issued a judgment in Hologic’s favor two weeks
before trial, holding that Minerva’s patent is invalid.
Today’s affirmation by the U.S. Court of Appeals follows a prior
decision against Minerva. In a separate matter between Hologic and
Minerva, a Delaware district court found Minerva liable for
infringing a Hologic patent. The U.S. Court of Appeals rejected
Minerva’s arguments on appeal and as a result, Minerva had to pay
Hologic more than $7.4 million.
About NovaSure
The FDA approved the NovaSure endometrial ablation procedure in
2001 as safe and effective for women who suffer from abnormal
uterine bleeding (AUB). The procedure provides a minimally invasive
treatment option for women seeking an alternative to hormones or
hysterectomy to treat their AUB, and since its introduction, more
than 3 million women have been treated. The procedure has an
efficacy rate of 77.7% and a demonstrated 92.8% patient
satisfaction rate at one-year follow-up of the pivotal clinical
trial.1
About Hologic
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women’s health and well-being
through early detection and treatment. For more information on
Hologic, visit www.hologic.com.
Hologic, NovaSure, The Science of Sure and associated logos are
trademarks and/or registered trademarks of Hologic Inc. and/or its
subsidiaries in the United States and/or other countries. All other
trademarks, registered trademarks and product names are the
property of their respective owners.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
1NovaSure Instructions for Use
Source: Hologic Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230217005046/en/
Media Contact: Jane Mazur Vice President, Communications
(+1) 508.263.8654 jane.mazur@hologic.com
Investor Contact: Ryan Simon Vice President, Investor
Relations (+1) 858.410.8514 ryan.simon@hologic.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Jul 2023 to Jul 2024